Inhospital mortality among clinical and surgical inpatients recently diagnosed with venous thromboembolic disease

Abstract

Venous thromboembolism (VTE) is the most common cause of preventable mortality in hospitalized patients, and pulmonary embolism is responsible for 5-10 % of all hospital deaths. To estimate the hospital mortality in hospitalized patients who developed VTE during hospitalization. Prospective cohort of all adult inpatients >17 years admitted to the hospital between August 2006 and August 2013, and follow-up until discharge to measure death. VTE incident cases were captured prospectively from the Institutional Registry of Thromboembolic disease in a tertiary hospital care in Buenos Aires. In hospital global mortality and fatality rate of inpatients with VTE was calculated. The cumulative incidence of VTE was 1.8 % (95 % CI 1.77-1.93 %), representing 1.32 % (95 % CI 1.23-1.41 %) in the subgroup of surgical patients and 2.1 % (95 % CI 1.9-2.2 %) in clinical inpatients. The overall hospital mortality was 2.4 % (95 % CI 2.35-2.53); being 3.95 % (95 % CI 3.78-4.12) in clinical inpatients and 1.15 % (95 % CI 1.06-1.23) in surgical patients. The death in patients who had developed VTE, represented between 4 and 7 % of hospital deaths, and it increases with age in both clinical and surgical patients. In Argentina there are few data of hospital mortality in patients with VTE. This information is useful when assessing the need for resources for prevention, diagnosis and treatment in inpatients.

Incidence of hospital-acquired venous thromboembolic disease.

“…This study demonstrates, consistent with the literature [3][4][5]7,16] , the high risk of VTE in hospitalized patients, which is still a major health problem. Additionally, the data presented in person-days constitutes the first of this kind to cover data of hospitalized VTE incidence in Argentina.…”

“…Each person was followed contributing time-at-risk from admission to event manifestation, discharge or death. The clinical hospital mortality was 2011/50,841, 3.95 % (95%CI 3.78-4.12) and surgical 678/59,228, 1.15 % (95%CI 1.06-1.23) [7] . VTE (PE and/or DVT) occurred in 1072 hospitalizations, 34% (363) belonged to clinical patients.…”

“…The overall average annual incidence of VTE adjusted by age and gender in a cohort of patients who resided in Minnesota was 117 per 100000 (DVT, 48 per 100000; PE, 69 per 100000) [3] . The incidence rates of a first episode of VTE according to different series were between 0.71 and 1.17 cases per 1,000 persons of the Caucasian population [4][5][6][7] . From the Institutional Registry of Thromboembolic Disease (IRTD Home-ClinicalTrials.gov, NCT01372514), the incidence of DVT is 1.03, and 0.32 per 1,000 person-years of PE, with a mortality of 25% in patients with confirmed PE [1] .…”

Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients

“…It is associated with complications which require intense medical treatment. 24 Rivaroxaban was the first direct Xa inhibitor to be recommended for clinical application. It overcomes the limitations of traditional anticoagulants in Fig.…”

Occurrence of Hospital-Associated Thrombosis in the Setting of Current Thromboprophylaxis Strategies: An Observational Cross-Sectional Study

“…

Hospital-associated thrombosis (HAT) is a common potentially preventable cause of morbidity and mortality [1][2][3][4] . HAT can be effectively lowered by thromboprophylaxis [5][6][7] .

…”